Bb Biotech as of Dec. 31, 2014
Portfolio Holdings for Bb Biotech
Bb Biotech holds 28 positions in its portfolio as reported in the December 2014 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Celgene Corporation | 13.5 | $416M | 3.7M | 111.86 | |
| ISIS Pharmaceuticals | 11.9 | $369M | 6.0M | 61.74 | |
| Incyte Corporation (INCY) | 9.6 | $296M | 4.1M | 73.11 | |
| Gilead Sciences (GILD) | 9.0 | $278M | 2.9M | 94.26 | |
| Agios Pharmaceuticals (AGIO) | 6.8 | $209M | 1.9M | 112.04 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 5.2 | $161M | 1.4M | 118.80 | |
| Medivation | 4.5 | $138M | 1.4M | 99.61 | |
| Alexion Pharmaceuticals | 4.0 | $124M | 672k | 185.03 | |
| Radius Health | 3.5 | $107M | 2.8M | 38.91 | |
| Synageva Biopharma | 3.4 | $105M | 1.1M | 92.79 | |
| Puma Biotechnology (PBYI) | 3.2 | $99M | 522k | 189.27 | |
| Pharmacyclics | 2.9 | $89M | 732k | 122.26 | |
| Regeneron Pharmaceuticals (REGN) | 2.6 | $81M | 198k | 410.25 | |
| Receptos | 2.6 | $80M | 651k | 122.51 | |
| Alnylam Pharmaceuticals (ALNY) | 2.4 | $73M | 751k | 97.00 | |
| Neurocrine Biosciences (NBIX) | 2.2 | $69M | 3.1M | 22.34 | |
| Halozyme Therapeutics (HALO) | 2.1 | $66M | 6.8M | 9.65 | |
| Ptc Therapeutics I (PTCT) | 2.1 | $64M | 1.2M | 51.77 | |
| Tetraphase Pharmaceuticals | 1.7 | $52M | 1.3M | 39.71 | |
| Novavax | 1.5 | $47M | 7.9M | 5.93 | |
| Infinity Pharmaceuticals (INFIQ) | 1.3 | $39M | 2.3M | 16.89 | |
| Clovis Oncology | 1.1 | $35M | 618k | 56.00 | |
| Tesaro | 0.8 | $26M | 705k | 37.19 | |
| ImmunoGen | 0.6 | $20M | 3.2M | 6.10 | |
| Cempra | 0.6 | $18M | 775k | 23.51 | |
| Theravance | 0.5 | $15M | 1.0M | 14.15 | |
| Achillion Pharmaceuticals | 0.4 | $13M | 1.1M | 12.25 | |
| Cubist Pharmaceutic-cvr | 0.0 | $35k | 876k | 0.04 |
